Drug intelligence / Profile preview

doxorubicin or epirubicin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Intravesical

Overview

**Doxorubicin** and **epirubicin** are distinct anthracycline antineoplastic antibiotics; epirubicin is a stereoisomeric analog of doxorubicin. Both intercalate into DNA, inhibit topoisomerase II, and promote oxidative damage, causing DNA strand breaks and cancer-cell death. They are established cytotoxic chemotherapies used principally in breast cancer and in multi-agent regimens for other malignancies. The supplied clinical-trial text uses \"doxorubicin (epirubicin)\" as an alternative anthracycline component rather than identifying one single active substance.

Brand names: AdriamycinEllence
Other names: doxorubicinepirubicin

Targets

DNATOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on doxorubicin or epirubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin or epirubicin.

Explore the full profile